To include your compound in the COVID-19 Resource Center, submit it here.

PCI-32765: Phase II started

Last quarter, Pharmacyclics began the open-label, U.S. Phase II PCYC-1108 trial evaluating 420 mg oral PCI-32765 daily in combination with bendamustine and rituximab or fludarabine, cyclophosphamide and rituximab in about

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE